tiprankstipranks
Pulmatrix (PULM)
NASDAQ:PULM

Pulmatrix (PULM) Stock Price & Analysis

766 Followers

PULM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.64 - $4.49
Previous Close$1.96
Volume9.94K
Average Volume (3M)11.08K
Market Cap
$7.19M
Enterprise Value-$5.52M
Total Cash (Recent Filing)$21.34M
Total Debt (Recent Filing)$8.62M
Price to Earnings (P/E)-0.4
Beta0.87
Mar 28, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.46
Shares Outstanding3,652,285
10 Day Avg. Volume13,463
30 Day Avg. Volume11,077
Standard Deviation0.20
R-Squared0.05
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.36
Price to Sales (P/S)1.18
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.81
Enterprise Value/Gross Profit-0.91
Enterprise Value/Ebitda8.72
Forecast
Price Target Upside437.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1


Financials

Annual

Ownership Overview

0.00%
Insiders
2.18% Mutual Funds
4.73% Other Institutional Investors
93.08% Public Companies and
Individual Investors

PULM FAQ

What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was $1.64 and its highest was $4.49 in the past 12 months.
    What is Pulmatrix’s market cap?
    Currently, no data Available
    When is Pulmatrix’s upcoming earnings report date?
    Pulmatrix’s upcoming earnings report date is Mar 28, 2024 which is in 109 days.
      How were Pulmatrix’s earnings last quarter?
      Pulmatrix released its earnings results on Nov 09, 2023. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.05 by $0.02.
        Is Pulmatrix overvalued?
        According to Wall Street analysts Pulmatrix’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Pulmatrix pay dividends?
          Pulmatrix does not currently pay dividends.
          What is Pulmatrix’s EPS estimate?
          Pulmatrix’s EPS estimate is -$1.04.
            How many shares outstanding does Pulmatrix have?
            Pulmatrix has 3,652,285 shares outstanding.
              What happened to Pulmatrix’s price movement after its last earnings report?
              Pulmatrix reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.05. Following the earnings report the stock price went down -3.646%.
                Which hedge fund is a major shareholder of Pulmatrix?
                Currently, no hedge funds are holding shares in PULM

                ---

                Pulmatrix Stock Smart Score

                N/A
                Not Ranked
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10
                Learn more about TipRanks Smart Score

                Company Description

                Pulmatrix

                Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.

                ---

                Top 5 ETFs holding PULM

                Name
                Market Value
                Smart Score
                iShares Core S&P Total U.S. Stock Market ETF
                $1.95
                8
                Up to five ETFs with an Outperform Smart Score that hold PULM. The ETFs are listed according to market value of PULM within the ETF

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                Aptose Biosciences
                Fate Therapeutics
                Innoviva
                RedHill Biopharma

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis